Wedbush lowered the firm’s price target on Apellis (APLS) to $18 from $20 and keeps a Neutral rating on the shares. Overall, the Q4 report from Apellis was largely as anticipated with the company preannouncing key results in January, the firm notes. Management anticipates flat Syfovre pricing into FY26 and more limited growth.
Claim 50% Off TipRanks Premium
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLS:
Disclaimer & DisclosureReport an Issue
Apellis price target lowered to $18 from $20 at Wedbush
Apellis price target lowered to $44 from $45 at Citi
Balanced Outlook on Apellis: Near-Term Revenue Uncertainty and Developing Long-Term Upside Justify Hold Rating
Apellis price target raised to $48 from $45 at H.C. Wainwright
Apellis Pharmaceuticals: Buy Rating Supported by Blockbuster Empaveli Potential, Sustainable Syfovre Growth, and Expanding Kidney Franchise
